Cargando…

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns

Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present chall...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetteh, Raymond A., Yankey, Barbara A., Nartey, Edmund T., Lartey, Margaret, Leufkens, Hubert G. M., Dodoo, Alexander N. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362649/
https://www.ncbi.nlm.nih.gov/pubmed/28130774
http://dx.doi.org/10.1007/s40264-017-0505-6
_version_ 1782516993099825152
author Tetteh, Raymond A.
Yankey, Barbara A.
Nartey, Edmund T.
Lartey, Margaret
Leufkens, Hubert G. M.
Dodoo, Alexander N. O.
author_facet Tetteh, Raymond A.
Yankey, Barbara A.
Nartey, Edmund T.
Lartey, Margaret
Leufkens, Hubert G. M.
Dodoo, Alexander N. O.
author_sort Tetteh, Raymond A.
collection PubMed
description Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry “http://www.clinicaltrials.gov” and scholar.google, using combination search terms ‘pre-exposure prophylaxis’, ‘safety concerns in the use of pre-exposure prophylaxis’, ‘truvada use as PrEP’, ‘guidelines for PrEP use’, ‘HIV pre-exposure prophylaxis’ and ‘tenofovir’ to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.
format Online
Article
Text
id pubmed-5362649
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-53626492017-04-04 Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns Tetteh, Raymond A. Yankey, Barbara A. Nartey, Edmund T. Lartey, Margaret Leufkens, Hubert G. M. Dodoo, Alexander N. O. Drug Saf Review Article Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry “http://www.clinicaltrials.gov” and scholar.google, using combination search terms ‘pre-exposure prophylaxis’, ‘safety concerns in the use of pre-exposure prophylaxis’, ‘truvada use as PrEP’, ‘guidelines for PrEP use’, ‘HIV pre-exposure prophylaxis’ and ‘tenofovir’ to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use. Springer International Publishing 2017-01-28 2017 /pmc/articles/PMC5362649/ /pubmed/28130774 http://dx.doi.org/10.1007/s40264-017-0505-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Tetteh, Raymond A.
Yankey, Barbara A.
Nartey, Edmund T.
Lartey, Margaret
Leufkens, Hubert G. M.
Dodoo, Alexander N. O.
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title_full Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title_fullStr Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title_full_unstemmed Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title_short Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
title_sort pre-exposure prophylaxis for hiv prevention: safety concerns
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362649/
https://www.ncbi.nlm.nih.gov/pubmed/28130774
http://dx.doi.org/10.1007/s40264-017-0505-6
work_keys_str_mv AT tettehraymonda preexposureprophylaxisforhivpreventionsafetyconcerns
AT yankeybarbaraa preexposureprophylaxisforhivpreventionsafetyconcerns
AT narteyedmundt preexposureprophylaxisforhivpreventionsafetyconcerns
AT larteymargaret preexposureprophylaxisforhivpreventionsafetyconcerns
AT leufkenshubertgm preexposureprophylaxisforhivpreventionsafetyconcerns
AT dodooalexanderno preexposureprophylaxisforhivpreventionsafetyconcerns